MX2022007292A - Formulaciones de farmacos polibásicos para reducir la toxicidad multiorgánica. - Google Patents

Formulaciones de farmacos polibásicos para reducir la toxicidad multiorgánica.

Info

Publication number
MX2022007292A
MX2022007292A MX2022007292A MX2022007292A MX2022007292A MX 2022007292 A MX2022007292 A MX 2022007292A MX 2022007292 A MX2022007292 A MX 2022007292A MX 2022007292 A MX2022007292 A MX 2022007292A MX 2022007292 A MX2022007292 A MX 2022007292A
Authority
MX
Mexico
Prior art keywords
formulations
drugs
reduce
toxicity
organ toxicity
Prior art date
Application number
MX2022007292A
Other languages
English (en)
Inventor
Manu Chaudhary
Original Assignee
Manu Chaudhary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manu Chaudhary filed Critical Manu Chaudhary
Publication of MX2022007292A publication Critical patent/MX2022007292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones y formulaciones de fármacos polibásicos para reducir la toxicidad multiorgánica mediante la elaboración de complejos catiónicos supramoleculares sin formación de enlaces covalentes, sin conjugación y sin modificación química de la entidad macromolecular utilizada. Las composiciones y formulaciones hechas de las mismas actúan por múltiples mecanismos simultáneamente para reducir la toxicidad de los fármacos antibióticos catiónicos.
MX2022007292A 2019-12-14 2020-12-13 Formulaciones de farmacos polibásicos para reducir la toxicidad multiorgánica. MX2022007292A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201911051914 2019-12-14
PCT/IN2020/051027 WO2021117065A1 (en) 2019-12-14 2020-12-13 Formulations of polybasic drugs to reduce multi-organ toxicity

Publications (1)

Publication Number Publication Date
MX2022007292A true MX2022007292A (es) 2022-11-14

Family

ID=76329703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007292A MX2022007292A (es) 2019-12-14 2020-12-13 Formulaciones de farmacos polibásicos para reducir la toxicidad multiorgánica.

Country Status (13)

Country Link
US (1) US20230104323A1 (es)
EP (1) EP4072563A4 (es)
JP (1) JP2023516848A (es)
CN (1) CN115003311B (es)
BR (1) BR112022011800A2 (es)
CA (1) CA3164789A1 (es)
CO (1) CO2022009909A2 (es)
IL (1) IL293883A (es)
JO (1) JOP20220144A1 (es)
MX (1) MX2022007292A (es)
PE (1) PE20221572A1 (es)
WO (1) WO2021117065A1 (es)
ZA (1) ZA202207816B (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6275800A (en) * 1999-07-16 2001-02-05 Mallinckrodt, Inc. Inhibition of renal uptake of molecules that are potentially damaging for the kidney
FI20010764A0 (fi) * 2001-04-11 2001-04-11 Map Medical Technologies Oy Kationiset dekstraanijohdannaiset käytettäväksi munuaisten suojaamiseen
AU2002307802A1 (en) * 2002-04-25 2003-10-08 Recepticon Aps Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents
JP2006520761A (ja) * 2003-03-26 2006-09-14 レセプトイコン・アンパルトセルスカブ 薬物誘発性細胞毒性の予防のための化合物の使用
KR20110058887A (ko) * 2008-09-18 2011-06-01 마누 차우드하리 신규한 단일 유닛 카바페넴 아미노글라이코사이드 제형
EP2475358B1 (en) * 2009-09-09 2019-06-05 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
US10953070B2 (en) * 2014-07-25 2021-03-23 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
CA3040795A1 (en) * 2016-10-21 2018-04-26 Algipharma As Polymyxin-alginate oligomer conjugates

Also Published As

Publication number Publication date
ZA202207816B (en) 2023-03-29
CO2022009909A2 (es) 2022-07-19
CN115003311A (zh) 2022-09-02
EP4072563A1 (en) 2022-10-19
CN115003311B (zh) 2024-04-19
EP4072563A4 (en) 2024-01-24
JP2023516848A (ja) 2023-04-21
PE20221572A1 (es) 2022-10-06
CA3164789A1 (en) 2021-06-17
US20230104323A1 (en) 2023-04-06
BR112022011800A2 (pt) 2022-08-30
WO2021117065A1 (en) 2021-06-17
JOP20220144A1 (ar) 2023-01-30
IL293883A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
AU2021295423B2 (en) Quinoxaline derivatives as anti-cancer drugs
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
CY1116156T1 (el) Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο
SE0101675D0 (sv) Novel composition
MX2022003740A (es) Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
HRP20070076A2 (en) Pyrimidine derivatives
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
MXPA05012026A (es) Compuestos de azaindol como inhibidores de cinasa.
MX2010009646A (es) Agentes terapeuticos antivirales.
MY197127A (en) Pyrrolobenzodiazepine conjugates
HK1129376A1 (en) Novel imidazole derivatives, preparation and user thereof as medicine
WO2007066337A3 (en) Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2022004875A (es) Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos.
BRPI0506535A (pt) pirroles bis-indole úteis como agentes anti-microbiais
TW200510364A (en) Flavanone compound and uses thereof
MX2009011254A (es) Derivados de purinas sustituidas que contienen 2,6-dinitrogeno, preparacion y usos de los mismos.
WO2007067333A3 (en) Trioxane dimers having high anticancer and long-lasting antimalarial activities
WO2019241644A8 (en) Novel small molecule anticancer agents, combinations and uses thereof
WO2005054172A3 (en) Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
JOP20220144A1 (ar) صيغ من عقاقير متعددة القواعد لتقليل السُمية لعدة أعضاء
MX2021004379A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen.